Drug Payment Experiments Coming To Medicare, Medicaid
Executive Summary
Centers For Medicare and Medicaid Services releases 'request for information' on how to approach development of new payment models for prescription drugs in government-sponsored insurance.
You may also be interested in...
Value-Based Payment Experiments For Drugs To Be Key Focus For CMMI, Director Says
Recently-installed Center for Medicare and Medicaid Innovation Chief Adam Boehler says payment lab will play a role in the Administration’s overall approach to lowering prescription drug costs.
Pricing Positives From Trump Plan Include Potential 340B Changes, Value-Based Contracts
Industry should be encouraged by Blueprint's interest in examining impact of Medicaid rebates, the annual excise tax, and the 340B program. Document also confirms Administration’s interest in value-based contracting.
Trump's Drug Pricing Plans On Slow Walk? HHS To Solicit Comment On Policies
No big policy implementation expected to be announced during president's speech planned for next week. HHS will continue to gather feedback on various approaches to lowering drug pricing.